What's Changing

On August 10, 2026, the U.S. Department of Health and Human Services and the FDA announced a proposed rule that would end one of the food industry's longest-standing regulatory gaps: the ability of a company to conclude, entirely on its own, that an ingredient is Generally Recognized as Safe (GRAS) — without ever telling the FDA. The rule was published in the Federal Register on August 11, and would amend 21 CFR Parts 170 and 570, covering both human and animal food.

Under the current framework, a company can reach a GRAS conclusion internally, sometimes with an outside expert panel, and market the ingredient without notifying the FDA at all. Notification has been encouraged since 2016 but never required. The proposed rule would make notification mandatory, subject to seven defined exceptions, for most new and existing GRAS uses in the U.S. food and feed supply.

Why FDA Is Doing This Now

The proposal follows a March 2025 directive from HHS Secretary Robert F. Kennedy Jr. instructing the FDA to eliminate the pathway that lets companies self-affirm GRAS status without government visibility. FDA has framed the change as closing an information gap, not redefining what "safe" means — the GRAS category itself is not being eliminated, only the ability to reach that conclusion in private.

Acting FDA Commissioner Kyle Diamantas described the rule as closing a decades-old information gap, while noting the agency is respecting the limits of its own statutory authority — an acknowledgment of ongoing legal debate over whether the FDA can compel this kind of disclosure at all.

What Companies Would Actually Have to Do

Under the proposal, any company introducing a substance into U.S. commerce on the basis of a GRAS conclusion would need to notify the FDA of that conclusion and its supporting scientific basis — unless one of seven exceptions applies. Exceptions include certain animal-food ingredients already listed in AAFCO's 2024 Official Publication, and substances covered by an existing, publicly available FDA consultation summary.

Substances already on the market under an independent GRAS conclusion would not be forced to stop sale immediately. A time-limited streamlined submission pathway would let companies transition existing uses with a lighter filing than a full new GRAS notice — but only for uses introduced into commerce before a final rule's effective date. Companies that fail to submit required data risk having it treated as non-confidential and subject to disclosure.

A Market-Access Signal, Not Just a Compliance One

SFT Editorial Analysis: legal reviews of the proposal have flagged that mandatory, resource-intensive notification could slow the pace at which new ingredients reach the market, particularly as the FDA works through recent staffing reductions across its Human Foods Program and Center for Veterinary Medicine. For ingredient developers and food manufacturers everywhere — not only in the U.S. — the practical effect is the same: the ability to produce a complete, defensible safety file for an ingredient is becoming as commercially important as the ingredient's function itself.

That shift matters beyond U.S. borders. Global food companies increasingly design formulations to travel across markets rather than being rebuilt for each one. A product built from the outset on well-documented ingredients — with a clear scientific basis, sourcing history, and regulatory file — is better positioned to move into new markets quickly than one that has to be reformulated or re-justified each time a regulator asks harder questions.

What This Means for Saudi and MENA Manufacturers

For Saudi Arabia's growing food manufacturing base — much of it built around export ambitions and import substitution under Vision 2030 — the U.S. move is a useful early signal rather than a direct regulatory obligation. It reflects a broader global direction: regulators in major markets are asking for more transparency on how "safe" conclusions are reached, not less.

Manufacturers and ingredient suppliers positioning products for export, co-manufacturing, or licensing deals with U.S. or multinational partners should expect ingredient documentation — safety basis, sourcing, and functional data — to be requested earlier in commercial conversations, not only at the point of regulatory filing. Building that documentation discipline into product development now is lower-cost than retrofitting it later.

What We're Watching

Two questions will shape how much this proposal ultimately matters. First, whether it survives the comment period and legal scrutiny over FDA's statutory authority to compel disclosure, and becomes a final rule as proposed. Second, whether other food-safety regulators — in the EU, UK, or across the Gulf — follow the U.S. toward higher ingredient-disclosure standards, which would raise the documentation bar for any company building products meant to move across borders.